• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news

Hybrid artificial fish particle swarm optimizer and kernel extreme learning machine for type-II diabetes predictive model
AbstractThe World Health Organization(WHO) estimated that in 2016, 1.6 million deaths caused were due to diabetes. Precise and on-time diagnosis of type-II diabetes is crucial to reduce the risk of various diseases such as heart disease, stroke, kidney disease, diabetic retinopathy, diabetic neuropathy, and macrovascular problems. The non-invasive methods like machine learning are reliable and efficient in classifying the people subjected to type-II diabetics risk and healthy people into two different categories. This present study aims to develop a stacking-based integrated kernel extreme learning machine (KELM) model for...
Source: Medical and Biological Engineering and Computing - March 18, 2021 Category: Biomedical Engineering Source Type: research